Investor Relations Home
Rigel currently has the following product candidates in development: fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase 3 clinical trials for ITP and initiating a Phase 2 clinical trial for IgA nephropathy (IgAN); R348, a topical JAK/SYK inhibitor, in a Phase 2 clinical trial for dry eye in ocular graft-versus-host disease (GvHD); two oncology product candidates in Phase 1 development with partners BerGenBio AG and Daiichi; and two preclinical programs with partners AstraZeneca for R256 in asthma and Bristol-Myers Squibb for TGF beta inhibitors in immuno-oncology.
Q2 2015 Rigel Pharmaceuticals Inc. Earnings Conference Call (Live)
August 4, 2015 at 4:30 p.m. ET
|07/28/15||Rigel Announces Conference Call and Webcast to Report Second Quarter 2015 Financial Results|
|SOUTH SAN FRANCISCO, Calif., July 28, 2015 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its second quarter 2015 financial results after market close on Tuesday, August 4, 2015. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30pm Eastern Time (1:30pm Pacific Time) to discuss the financial results.
Participants can access the live conference call by dialing 855-892-1489 (domestic) or 720-634-293... |
|06/30/15||Rigel Welcomes Keith A. Katkin to Board of Directors|
|SOUTH SAN FRANCISCO, Calif., June 30, 2015 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Keith A. Katkin, president and chief executive officer of Avanir Pharmaceuticals, has been appointed to Rigel's board of directors. Mr. Katkin brings to Rigel's board extensive biopharmaceutical experience in commercial development, business development and operational management.
"Keith's background in directing product launches and his successful leadership of Avani... |
|* Data collected 07/26/15 - 08/02/15|
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.